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Abstract 
Introduction: Cardiac troponins are sensitive and specific biomarkers of myocardial necrosis. 
We evaluated troponin, CK, and ECG abnormalities in patients with septic shock; and compared 
the effect of vasopressin (VP) vs norepinephrine (NE) on troponin, CK, and ECGs.  
Methods: This was a prospective substudy of a randomized trial. Adults with septic shock 
randomly received a blinded infusion of low-dose VP (0.01-0.03 U/min) or NE (5-15 µg/min) in 
addition to open-label vasopressors, titrated to maintain a mean blood pressure of 65-75 mmHg. 
Troponin I/T, CK, and CKMB were measured and 12-lead ECGs were recorded prior to study 
drug, and 6 hours, 2 days and 4 days after study drug initiation. Two physician readers, blinded 
to patient data and drug, independently interpreted ECGs. 
Results: We enrolled 121 patients [median age 63.9 years (IQR 51.1,75.3), mean APACHE II 
28.6 (SD 7.7)]: 65 in VP group and 56 in NE group. At the 4 timepoints, 26%, 36%, 32% and 
21% of patients had troponin elevations, respectively. Baseline characteristics and outcomes 
were similar between patients with positive versus negative troponin levels. Troponin and CK 
levels, and rates of ischemic ECG changes were similar in the VP and NE groups. In 
multivariable analysis only APACHE II was associated with 28-day mortality (OR 1.07, 95% CI 
1.01-1.14, p=0.033). 
Conclusions: Troponin elevation is common in adults with septic shock. We observed no 
significant differences in troponin, CK, and ECGs in patients treated with vasopressin and 
norepinephrine. Troponin elevation was not an independent predictor of mortality. 
Trial registration: Controlled-trials.com ISRCTN94845869. 
 
KEY WORDS: Septic shock, myocardial ischemia, vasopressin, norepinephrine, troponin, 
electrocardiogram. 
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Introduction 
Cardiac ischemia occurs frequently in critically ill patients, and is associated with 
increased mortality [1]. Given that most critically ill patients cannot communicate symptoms, the 
diagnosis of cardiac ischemia can be challenging and necessitates that clinicians rely on cardiac 
biomarkers and electrocardiograms (ECGs). Patients receiving vasopressors may be at even 
higher risk of cardiac ischemia than other patients because of coronary artery vasoconstriction, 
increased systemic vasoconstriction-induced afterload [2], or catecholamine-driven increases in 
myocardial oxygen demand. 
The Vasopressin in Severe Sepsis Trial (VASST) randomized patients with septic shock 
to vasopressin or norepinephrine [3]. Overall, there was no significant difference in the primary 
outcome (28-day mortality) between the vasopressin and the norepinephrine groups (35.4% vs 
39.3% respectively, p=0.26). Further, there were no differences in the clinical diagnosis of 
myocardial infarction/ischemia in the two groups (2.0% vs 1.8%, P=1.0), nor in the incidence of 
cardiac arrest, tachyarrhythmias or bradyarrhythmias. Vasopressin and norepinephrine are both 
potent vasoconstrictors, and animal studies suggest that vasopressin is associated with 
coronary vasoconstriction and myocardial depression [4,5]. Therefore, we conducted a 
prospective study to examine, in more detail, ischemic ECG changes, troponin and creatine 
kinase (CK) levels, and clinical outcomes in a subset of patients enrolled in the VASST Trial. 
Our specific objectives were to describe troponin and CK levels and ECG abnormalities in 
patients with severe septic shock; and to compare the effect of vasopressin vs norepinephrine 
on troponin and CK levels, ECGs and the clinical diagnosis of acute myocardial infarction. 
 
Materials and methods 
Study Design: This study evaluating the incidence of cardiac ischemia was a prospective 
observational sub-study, performed as part of the Vasopressin And Septic Shock Trial (VASST), 
a double-blind randomized controlled trial of vasopressin vs norepinephrine in patients with 
septic shock [3]. We previously published a manuscript assessing intra- and inter-rater 
agreement of electrocardiogram interpretation in these patients [6]. VASST enrolment occurred 
between July 2001 and April 2006. This investigator-initiated substudy started after enrolment in 
the VASST Trial had begun, and thus was not included in the trial registration 
(ISRCTN94845869). Nine Canadian sites participated in this sub-study, after obtaining local 
institutional research ethics board approval (St. Paul’s Hospital, Vancouver General Hospital, 
Richmond General Hospital, University Health Network - Toronto General Hospital, University 
Health Network - Toronto Western Hospital, Mount Sinai Hospital, St. Michael's Hospital, St. 
 4
Joseph's Hospital, Hotel Dieu Grace Hospital; see Additional file for locations). Written informed 
consent was obtained from all patients or their surrogate.  
 
Patients: All patients enrolled in VASST in 9 participating centers were included in this substudy. 
Patients were greater than 16 years of age and had septic shock, defined by the presence of 
two or more of the systemic inflammatory response syndrome (SIRS) criteria, proven or 
suspected infection, new dysfunction of at least one organ, and hypotension despite adequate 
fluid resuscitation requiring vasopressor support of at least 5 µg/min of norepinephrine (or 
equivalent) for 6 hours. More severe septic shock was defined as treatment with 15 µg or more 
of norepinephrine or the equivalent per minute. Specific cardiac exclusion criteria of VASST 
were: unstable coronary syndrome (acute myocardial infarction during this episode of shock 
based on the combination of history, electrocardiogram, and enzyme changes as defined by the 
investigator), and underlying chronic heart disease (NYHA class III or IV). Patients were 
randomized to receive a blinded infusion of study drug, either vasopressin (0.01 - 0.03 U/min) or 
norepinephrine (5–15 µg/min). The study drug and all other vasopressors were titrated and 
weaned according to protocols, with an initial target mean arterial pressure of 65–75 mmHg. 
Study drug infusions were stopped if there was a serious adverse event that was thought to be 
directly related to study drug infusion. 
 
Twelve-lead ECG recording and interpretation: 12-lead ECGs were recorded at baseline (prior 
to study drug infusion), and 6 hrs, 2 days, and 4 days after initiation of study drug, yielding a 
total of 373 ECGs. ECGs were read by 2 reviewers who were blinded to randomization group 
and troponin levels, using a checklist to standardize the interpretation. Prior to the ECG 
interpretation, a calibration exercise was performed by the 2 reviewers to refine definitions and 
maximize inter-observer agreement: this exercise and the checklist have been previously 
published [4]. Each ECG was analyzed for rhythm, and presence of Q waves, ST elevation, ST 
depression, and T wave inversion. Additionally, the readers assessed whether the ECG was 
normal or abnormal, and whether, in their opinion, the ECG changes represented ischemia.  
 
Serum cardiac markers: Troponin I or T, CK and CK-MB levels were measured in all patients at 
the same time-points as the ECG recordings. Of the 9 sites, 6 measured troponin I (Abbott 
Laboratories, Abbott Park, Illinois; or Dade Behring Inc, Newark, Delaware), 2 measured 
troponin T (Roche Diagnostics, Basel, Switzerland), and 1 switched the assay from troponin I to 
T during the trial. Table 1 illustrates multi-institutional laboratory troponin criteria used to 
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diagnose myocardial ischemia or infarction; we also categorized troponin as normal, weakly 
positive, and highly positive. We further categorized patients regarding troponin elevation. They 
were categorized as ‘highly positive’ if they had a highly positive troponin at any time point. If 
they never had a highly positive troponin, and had a weakly positive troponin at any time point, 
they were categorized as ‘weakly positive’. They were categorized as ‘normal’ if they had no 
troponin elevation at any time point. 
 
Ischemia based on ECG: Patients were categorized as having no ischemia, possible ischemia, 
or probable ischemia, based on ECG interpretations. Patients categorized as having no 
ischemia were those for whom both readers agreed on the absence of ischemic changes on all 
of their ECGs. Patients categorized as having probable ischemia were those for whom both 
readers agreed on the presence of ischemic changes on any single ECG. The remainder of 
patients were categorized as having possible ischemia, defined as the presence of ischemia on 
any 1 ECG, without agreement between the 2 readers. In addition, at each site, using all 
available clinical data, including troponin levels, the local investigator independently assessed in 
real time whether the patient met criteria for acute myocardial infarction. 
 
Statistical analysis 
Continuous data are reported as mean and SD, or median and interquartile range when 
not normally distributed. Binary data are reported as counts and proportions. Categorical 
variables were compared using Fisher’s exact test, and continuous variables were compared 
using Wilcoxon rank sum test. Linear and logistic mixed effects models were used to assess the 
differences between treatment groups across times, assuming there were no time trends. In 
logistic regression, we examined factors associated with 28-day mortality in univariate then 
multivariate analysis. Candidate independent variables were patient age, APACHE II score, 
more severe shock (defined as treatment with ≥15 µg/minute of norepinephrine or the 
equivalent), history of diabetes, history of ischemic heart disease, vasopressin vs 
norepinephrine infusion, possible or probable ECG evidence of ischemia, and troponin 
elevation. Calculations were performed using R Version 2.8.1 (R Foundation for Statistical 
Computing, Vienna, Austria). 
 
Results 
Compared with 657 VASST patients who were not enrolled in this substudy, the 121 
patients included in this substudy were similar, other than a higher percentage of males (70.3% 
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vs 59.3%, p=0.026) and higher APACHE II (mean 28.6 vs. 26.8, p=0.007). Of the 121 patients, 
65 were randomized to vasopressin, and 56 to norepinephrine; baseline characteristics and 
outcomes of the two groups were similar (Table 2). Enrolled patients were severely ill, as 
indicated by APACHE II scores, the proportion with new organ dysfunction, serum lactate levels, 
and by norepinephrine infusion doses at study entry.  
Mean arterial blood pressure (MAP) was similar in the two treatment groups throughout 
the study, whereas the heart rate was significantly lower in the vasopressin group than in the 
norepinephrine group during the first 4 days of treatment (P=0.033) (Figure 1, Additional file). 
The rate of norepinephrine infusion was significantly lower in the vasopressin group than in the 
norepinephrine group during the first 4 days (P=0.004) (Figure 2, Additional file). There were no 
statistically significant differences in serum creatinine between the norepinephrine and 
vasopressin groups (Figure 3, Additional File). 
 
Troponin, CK and CKMB levels 
Troponin elevation was common, occurring in 26%, 36%, 32% and 21% of patients at 
baseline, 6 hours, day 2 and day 4, respectively. There were no differences in baseline 
characteristics, organ failures, or mortality between patients with normal, weakly positive or 
highly positive troponin levels, except that patients with weakly or highly positive troponin had a 
higher incidence of underlying ischemic heart disease (Table 3, and Table 7, additional file). In 
addition, the rates of acute myocardial infarction, diagnosed by local site investigators, were 
higher in the patients with elevated troponin (Table 3). 
Five patients (2 in vasopressin group, 3 in norepinephrine group) had acute myocardial 
infarction diagnosed clinically, using symptoms, ECGs, and serum cardiac biomarkers. There 
were no significant differences in troponin, CK and CKMB levels in patients randomized to 
vasopressin versus norepinephrine at any of the time points (Table 4). Further, the percentages 
of patients with weakly positive troponin (27.6% vs 22.7%) and highly positive troponin (13.8% 
vs 15.2%) were similar between the vasopressin and norepinephrine groups, respectively.  
 
Electrocardiograms and ischemia 
Table 5 presents blinded interpretation of ECGs in patients randomized to vasopressin 
versus norepinephrine. More patients in the norepinephrine than the vasopressin group had Q 
waves (baseline, 6 hours, day 2, and day 4); there were no other differences in ECGs between 
groups. In the pooled cohort, there was no association between specific ECG findings or the 
presence of ECG ischemia at any time point, and 28-day mortality (Table 8, additional file).  
 7
We were interested to determine whether the presence or absence of cardiac ischemia 
on ECG was associated with different clinical outcomes. There were no differences in baseline 
characteristics or outcomes in patients with (N=56) or without (N=60) ECG ischemia (Table 6), 
even if troponin was elevated (Table 9, additional file). Sixty patients (51.7%) had no ischemia 
on any ECG at any time point, 39 (33.6%) patients had possible ECG ischemia, (defined as 
ischemia on any 1 ECG without agreement between the 2 readers) and 17 patients (14.6%) had 
probable ECG ischemia (defined as ischemia on any 1 ECG and both readers agreed).  
 
Logistic regression 
In the univariable analysis only age (OR 1.03; 95% CI 1.00-1.05; P=0.028), APACHE II 
(OR 1.08; 95% CI 1.02-1.14; P=0.005) and the presence of more severe shock (OR 2.32; 95% 
CI 1.11-4.88; P=0.025) were associated with 28 day mortality. In the multivariable analysis, only 
APACHE II score (OR 1.07, 95% CI 1.01-1.14, p=0.033) was highly associated with 28-day 
mortality.  
 
Sensitivity analyses 
ECGs and troponin assays were not performed for some patients at some of the time 
points. Such missing data may result in an overestimate of abnormalities we observed, given 
that patients for whom clinicians recorded ECGs and troponin levels have a greater likelihood of 
being labelled as abnormal. We thus repeated our analyses in two different ways. First, we used 
only baseline ECG reading and troponin level as predictors. In a second analysis, we used the 
ECG reading and troponin level as time dependent covariates. Our overall results did not 
change in either analysis.  
 
Discussion  
Regarding our first objective, in this prospective substudy of patients who had septic 
shock enrolled in VASST, troponin elevations were very common, occurring in up to 36% of 
patients. However, troponin elevation in patients with septic shock was not associated with 
increased mortality, compared with patients with no troponin elevation. Cardiac ischemia on 
ECGs was also common, occurring in 48% of patients at one or more of the measured time 
points; however cardiac ischemia on ECG was not predictive of worse outcomes.  
Regarding our second objective, there were no significant differences in troponin and creatine 
kinase levels between vasopressin and norepinephrine-treated patients. In addition, the overall 
incidence of ECG cardiac ischemia was similar in the vasopressin and norepinephrine-treated 
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patients, although more patients in the norepinephrine group had Q waves. There was no 
difference between vasopressin and norepinephrine groups in the clinical diagnosis of acute 
myocardial infarction.  
High doses of norepinephrine may cause myocardial damage and this in turn may 
increase troponin levels; nonetheless, despite lower norepinephrine doses in the vasopressin 
group than in the norepinephrine group, there was no overall difference in markers of 
myocardial ischemia such as troponin, creatine kinase levels and ECG findings. It is relevant to 
note that heart rate was significantly lower in the vasopressin group than in the norepinephrine 
group over the first four days (P=0.033), yet again we found no overall difference in markers of 
myocardial ischemia. We did not find evidence that renal dysfunction contributed to any 
differences between vasopressin and norepinephrine groups in markers of myocardial ischemia 
in that our marker of renal function (serum creatinine over time) was not different between 
groups. These observations highlight the complexity and multiple factors that could contribute to 
myocardial ischemia in patients who have septic shock. 
In critically ill patients many mechanisms are likely responsible for the release of 
troponin into the systemic circulation, including impaired microvascular perfusion, reduced 
oxygen delivery to the heart, myocardial depression and cellular injury, and increased 
myocardial oxygen demand [7]. Although cardiac troponins are sensitive and relatively specific 
biomarkers of myocardial injury, elevations are not diagnostically specific for acute coronary 
syndrome, and can occur in the absence of coronary atherosclerotic disease [8]. Cardiac 
troponin elevation may be even less specific in critically ill patients, as many conditions are 
associated with increased troponin, including infection, sepsis, septic shock, hypotension, 
arrhythmias, pulmonary embolism, and renal insufficiency [9]. Troponin levels are frequently 
elevated in critically ill patients and are independently positively associated with short- and long-
term mortality [10-13]. In a systematic review, 43% of 3278 critically ill patients enrolled in 20 
studies had elevated troponin levels [12]. In adjusted analyses elevated troponin was 
associated with an increased risk of death (OR 2.5, 95% CI 1.9-3.4; P<.001); in unadjusted 
analyses it was associated with increased length of ICU stay of 3 days (95% CI 1.0-5.1 days; 
P=.004) and hospital stay of 2.2 days (95% CI -0.6-4.9 days; P=.12).  
While we found a similarly high prevalence of elevated troponin (approximately 30-35% 
of patients) in our study of patients who had septic shock, we did not find that increased 
troponin was associated with increased mortality. Published data regarding the prognostic value 
of troponin elevation in patients with sepsis syndrome is conflicting [14-22]. However, consistent 
with our results, most studies have not found that troponin elevation is an independent predictor 
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of mortality, after adjusting for other variables [14, 16-18]. In multivariate analyses, previous 
trials have identified greater severity of illness and the presence of shock as independent 
predictors of death, as we did in our study [14, 16-18,]. In contrast, while several small studies 
have found increased mortality in patients with sepsis who have elevated troponin levels [19-
21], only one study concluded that elevated cTnI was an independent prognosticator of mortality 
after adjusting for other significant variables (odds ratio, 2.020; 95% confidence interval, 1.153-
3.541; P=.014) [22]. It is not clear whether elevated troponin is not prognostic in septic shock, or 
whether patient heterogeneity, or differences in timing and frequency of troponin measurement 
in different studies account for these conflicting results. 
ECGs are used in addition to serum cardiac biomarkers to diagnose cardiac ischemia in 
critically ill patients who are unable to communicate symptoms. However, ECG findings 
suggestive of ischemia, such as ST-segment deviations, are common in critically ill patients and 
may be non-specific for diagnosis of acute cardiac ischemia. In our study, 48% of patients with 
septic shock had possible or probable ECG ischemia; however this was not prognostic of worse 
clinical outcomes, even with concomitant troponin elevation. Our prevalence rate of 48% is 
generally consistent with other relevant studies. Landesberg and colleagues monitored 
continuous 12 lead ECGs in 101 general ICU patients with known coronary artery disease, or 2 
or more risk factors for coronary artery disease [23]. Of these patients, 21% had ischemic ST-
segment changes, characterized in most by ST depression. Similarly, Kress and colleagues 
observed ST-segment elevation or depression on continuous 3-lead Holter monitoring in 24% of 
critically ill patients with risk factors for coronary artery disease, which was associated with a 
longer ICU stay [24]. In a prospective trial evaluating myocardial ischemia during mechanical 
ventilation and weaning, Frazier and colleagues observed ST-segment changes in 70% of 43 
patients, and these patients were 60% more likely to fail an initial weaning trial [25]. 
Both vasopressin and norepinephrine are potent vasoconstrictors. In VASST, there were 
no differences in cardiac (clinical ischemia or acute myocardial infarction based on symptoms, 
ECG, and biomarkers), mesenteric, cerebrovascular, or digital ischemic events in the 
vasopressin and norepinephrine-treated groups [3]. Similarly, in this VASST substudy, the rates 
of ECG ischemia and troponin elevations were similar in the vasopressin and norepinephrine 
groups. We did find a significantly higher rate of Q waves in the norepinephrine group compared 
to the vasopressin group. Several small uncontrolled studies [26-29] found occasional 
occurrence of cardiac ischemia during infusion of vasopressin, but the small sample size and 
lack of controls precludes conclusions regarding risk of cardiac ischemia due to vasopressin 
infusion. In contrast, vasopressin infusion is cardio-protective in models of myocardial ischemia 
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[30,31], and in patients with post-cardiotomy shock [32]. In other studies, norepinephrine 
infusion was associated with cardiac ischemia and elevation of serum troponin. In the study by 
Landesberg and colleagues, norepinephrine infusion significantly predicted prolonged (>60 
minutes) ischemia (odds ratio 3.08; CI 0.99-9.60; P=.05) and troponin elevation in 101 general 
ICU patients [23]. To the extent that vasopressin versus norepinephrine have different effects on 
overall cardiac function, we also found no difference between the effects of vasopressin and 
norepinephrine on cardiac output and cardiac function in another substudy of VASST [33]. 
The strengths of this substudy are the inclusion of patients meeting stringent criteria for 
septic shock, the multicenter representation, and prospective collection of both ECGs and 
troponin at 4 time points. Previous studies describing troponin levels in patients with sepsis 
have not evaluated concurrent ECGs. The ECG readers were blinded to randomization group 
and cardiac biomarkers. Concealed randomization of patients to blinded vasopressin or 
norepinephrine infusions permitted an unbiased comparison between the two groups. 
This study has limitations. While our sample size is modest, it is similar to or larger than 
many previous studies evaluating troponin levels in patients with sepsis [15-17,19,20]; however 
we cannot exclude the possibility that our study was underpowered to detect differences in 
important variables. Given that patients in the vasopressin group were also receiving 
norepinephrine, this study is not a direct comparison of the administration of vasopressin and 
norepinephrine. Our study was conducted prior to the introduction of sensitive troponin assays, 
with the potential that the older generation troponin assays were affected by renal insufficiency, 
resulting in false positive troponin elevation. However, this would apply to both groups of 
patients, as serum creatinine was similar in the vasopressin and norepinephrine treated 
patients. The generalizability of our results is limited by our exclusion of patients with unstable 
coronary syndrome (acute myocardial infarction based on the combination of history, ECG, and 
enzyme changes),underlying chronic heart disease (NYHA III and IV), anticipated to die within 
12 hours, or receiving open-label vasopressin. Given these exclusions, our study population 
may have been at low-moderate risk of coronary ischemia, and would thus underestimate the 
true prevalence of ischemia in a less restricted septic shock population. The lack of a reference 
standard for ECG interpretation precludes the accurate diagnosis of ischemia. Finally, we do not 
have data on cardiac output, central venous saturation, or cardiac ultrasound; thus we cannot 
comment on whether the observed troponin elevations indicate subclinical or more overt cardiac 
ischemia and dysfunction. 
 
Conclusions 
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Troponin elevation and ECG evidence of ischemia were common, occurring in 36% and 
48%, respectively, of a subgroup of patients with septic shock enrolled in VASST. There were 
no significant differences in serum troponin levels and ECG evidence of ischemia between the 
vasopressin and norepinephrine groups. In this study, neither increased troponin nor ECG 
evidence of ischemia predicted increased mortality risk.  
 
Key Messages 
• In this prospective substudy of patients who had septic shock enrolled in VASST, 
troponin elevations were very common, occurring in up to 36% of patients.  
• Troponin elevation in patients with septic shock was not associated with increased 
mortality, compared with patients with no troponin elevation.  
• Cardiac ischemia on ECGs was also common, occurring in 48% of patients at one or 
more of the measured time points; however cardiac ischemia on ECG was not predictive 
of worse outcomes. 
• There were no significant differences in troponin and creatine kinase levels between 
patients treated with vasopressin and norepinephrine, compared with those treated with 
norepinephrine alone. In addition, the overall incidence of ECG cardiac ischemia was 
similar in the two groups, and there was no difference in the clinical diagnosis of acute 
myocardial infarction. 
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Table 1. Troponin I and T interpretation 
 
 Troponin I (mcg/L) Troponin T (mcg/L) 
Normal ≤ 0.5 No myocardial injury < 0.05 Normal 
Weakly positive 0.6 – 2.3 Suggestive of 
myocardial injury 
0.05 - .09 Borderline 
0.10 - 0.49 Weakly positive 
Highly positive > 2.3 Suggestive of acute 
myocardial infarction 
>0.49 Positive 
 
Legend for Table 1. In this table we show the 2 different troponin biomarkers and how their 
levels were interpreted. 
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Table 2. Characteristics of patients in the troponin substudy 
 
Variable Vasopressin (N = 65) 
Norepinephrine 
(N = 56) 
Age, years 62.9 (51.2, 73.6) 65.5 (50.8, 76.1) 
Male sex, N (%) 43 (66) 42 (75) 
Surgical patient, N (%) 25 (39) 25 (45) 
APACHE II 28.1 (8.0) 29.2 (7.3) 
Preexisting conditions, N (%) 
   Ischemic heart disease 
   Chronic obstructive pulmonary disease 
   Chronic renal failure 
   Diabetes 
   Liver disease 
   Cancer 
   Solid-organ transplant 
   Corticosteroid use 
   Recent trauma 
 
9 (14) 
6 (9) 
8 (12) 
13 (20) 
12 (18) 
17 (26) 
4 (6) 
9 (14) 
1 (2) 
 
8 (14) 
11 (20) 
9 (16) 
13 (23) 
9 (16) 
13 (23) 
5 (9) 
8 (14) 
3 (5) 
New organ failure at randomization, N (%) 
   Cardiovascular 
   Respiratory 
   Renal 
   Hematology/coagulation 
   Neurological 
 
65 (100) 
58 (89) 
43 (66) 
20 (31) 
21 (32) 
 
56 (100) 
50 (89) 
41 (73) 
13 (23) 
18 (32) 
Number of organ dysfunctions at 
randomization 3.0 (2.0, 3.0) 3.0 (2.0, 4.0) 
Source of Infection, N (%) 
   Lung 
   Abdomen 
   Othera 
 
28 (43) 
19 (29) 
18 (28) 
 
28 (50) 
16 (29) 
12 (21) 
Hemodynamic variables at randomization 
   Systolic Blood Pressure (mm Hg) 
   Mean Arterial Pressure (mm Hg) 
   Arterial pH 
   Serum lactate (mmol/L) 
 
110.0 (98.0, 118.0) 
72.0 (67.0, 77.0) 
7.34 (7.3, 7.4) 
2.3 (1.5, 3.6) 
 
105.0 (95.0, 114.0) 
70.0 (65.0, 75.0) 
7.36 (7.3, 7.4) 
2.2 (1.6, 4.1) 
Vasoactive drug dosages at randomization 
   Norepinephrine (µg/min) 
   Epinephrine (µg/min) 
   Dopamine (µg/kg/min) 
   Dobutamine (µg/kg/min) 
   Phenylephrine (µg/min) 
 
14.9 (9.1, 26.6) 
30.0 (30.0, 30.0) 
3.1 (3.0, 6.0) 
6.3 (2.5, 12.5) 
66.5 (31.1, 133.2) 
 
18.1 (10.6, 30.0) 
25.2 (8.4, 42.0) 
8.2 (4.0, 17.0) 
7.5 (2.5, 10.0) 
104.7 (43.0, 134.5) 
Days alive free of mechanical ventilation (first 
28 days)  0.5 (0.0, 17.0) 1.0 (0.0, 16.0) 
ICU stayb, days  11.5 (6.0, 26.0) 13.0 (6.0, 12.0) 
Hospital stayb, days  26.5 (10.5, 74.0) 37.5 (18.5, 89.5) 
28 day mortalityc, N (%) 27 (42) 24 (43) 
90 day mortalityc, N (%) 31 (48) 32 (57) 
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Legend for Table 2. In this table we present baseline characteristics and outcomes of patients 
randomized to vasopressin and norepinephrine.  
 
Continuous variables are presented as median and interquartile range. APACHE II is expressed 
as mean and standard deviation. 
APACHE II = Acute Physiology and Chronic Health Evaluation II, ICU = intensive care unit. 
a. Other sites of infection included blood, skin, central nervous system, bones and joints, 
cardiac system and reproductive organs.  
b. Censored at day 90 if patient did not die or was not discharged prior to day 90. ICU and 
Hospital stay are from time of admission to ICU. 
c. Outcome of one patient in the vasopressin group was unknown and excluded from the 
calculations. 
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Table 3. Baseline Characteristics and Outcomes of Patients with and without Elevations in 
Serum Troponin 
 
 Troponin levels (N=120)a 
Variable 
Normal 
(N=72) 
Weakly positiveb 
(N=30) 
Highly positiveb 
(N=18) P value 
Age, years 62.7 (51.1, 72.6) 68.4 (47.8, 77.8) 63.2 (50.0, 73.4) 0.378 
Male, N (%) 51 (71) 22 (73) 12(67) 0.920 
Surgical patient, N (%) 34 (47) 8 (27) 7 (39) 0.152 
APACHE II 27.5 (7.6) 29.7 (6.6) 31.7 (8.6) 0.153 
Preexisting conditions, N (%)     
   Ischemic heart disease 6 (8) 8 (27) 3 (17) 0.041 
   Diabetes 14 (19) 9 (30) 3 (17) 0.469 
   Corticosteroid use 8 (11) 7 (23) 2 (11) 0.269 
New organ failure at 
randomization, N (%)     
   Respiratory 66 (92) 25 (83) 16 (89) 0.406 
   Renal 49 (68) 21 (70) 14 (78) 0.781 
   Hematology/coagulation 17 (24) 8 (27) 7 (39) 0.428 
   Neurological 20 (28) 14 (47) 5 (28) 0.173 
Clinical MIc, N (%) 0 (0) 2 (7) 3 (17) 0.004 
28 day mortalityd, N (%) 30 (42) 12 (41) 8 (44) 1.0 
90 day mortalityd, N (%) 40 (56) 14 (48) 8 (44) 0.612 
 
Legend for Table 3. In this table, we describe among 120 patients, the baseline characteristics 
and outcomes of patients with or without elevated serum troponin.  
 
Age is presented as median and first and third quartiles. APACHE II is presented as mean and 
standard deviation. P-value is based on Fisher’s exact test or Wilcoxon rank-sum test.  
a. One patient had no troponin data. 
b. See Table 1 for definitions of weakly positive and highly positive troponin levels. Patients 
were categorized based on ever having highly positive or weakly positive troponin at any time 
point. 
c. MI = myocardial infarction. At each site the local investigator independently assessed in real 
time whether the patient met clinical criteria for myocardial infarction. 
d. Outcome of one patient in the vasopressin group was unknown and excluded from the 
calculation.  
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Table 4. Troponin, CK and CKMB levels at each time point in patients randomized to 
vasopressin or norepinephrine. 
 
 Vasopressin group 
median (1st, 3rd quartile), N 
Norepinephrine group 
median (1st, 3rd quartile), N 
 
Time Baseline 6 hours Day 2 Day 4 Baseline 6 hours Day 2 Day 4 P 
value 
Troponin I 
(mcg/L) 
 
0.07 
(0.0, 0.54) 
48 
0.11 
(0.0, 0.71) 
44 
0.15 
(0.0, 0.60) 
39 
0.03 
(0.0, 0.24) 
35 
0.20 
(0.0, 0.39) 
44 
0.35 
(0.10,0.70) 
39 
0.21 
(0.0, 0.60) 
37 
0.14 
(0.0, 0.43) 
33 
 
0.230 
Troponin T 
(mcg/L) 
 
0.06 
(0.02, 0.09) 
14 
0.06 
(0.0, 0.14) 
11 
0.03 
(0.0, 0.09) 
12 
0.00 
(0.0, 0.02) 
9 
0.01 
(0.0, 0.42) 
11 
0.06 
(0.0, 0.38) 
10 
0.07 
(0.01, 0.35) 
12 
0.13 
(0.01, 0.39) 
8 
 
0.360 
CK  
(U/L) 
 
204  
(61, 487) 
54 
208 
(54, 435) 
48 
190 
(36, 452) 
50 
69 
(21, 189) 
45 
184 
(60, 309) 
46 
192 
(68, 438) 
46 
147 
(41, 296) 
45 
46 
(21, 222) 
39 
 
0.985 
CKMB  
(mcg/L) 
 
4.0 
(1.6, 6.9) 
16 
3.0 
(1.3, 6.0) 
15 
5.0 
(1.0, 16.0) 
14 
1.4 
(0.0, 3.1) 
14 
4.3 
(1.0, 8.0) 
14 
2.6 
(1.8, 17.2) 
12 
4.7 
(2.0, 16.0) 
13 
1.9 
(1.0, 6.0) 
10 
 
0.396 
 
 
Legend for Table 4. In this table we present serum levels of troponin, creatine kinase (CK), and 
creatine kinase-MB (CKMB) at each time point. 
P-value is based on linear mixed effects regression model and is for the null hypothesis of no 
difference in Troponin/CK/CKMB level between the treatment groups at 6 hours, day 2 and day 
4, adjusted for baseline value. Outcome variables were log transformed if they were not 
normally distributed. 
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Table 5. ECG Interpretation at each time point in patients randomized to vasopressin or 
norepinephrine (N=121)  
 
 Vasopressin (N=65) Norepinephrine (N=56) P value 
Variable, N (%) 
Baseline 
(N=61) 
6 hours 
(N=43) 
Day 2 
(N=44) 
Day 4 
(N=39) 
Baseline 
(N=54) 
6 hours 
(N=40) 
Day 2 
(N=48) 
Day 4 
(N=35) 
 
Normala 19 (31) 15 (35) 14 (32) 19 (49) 10 (19) 12 (30) 14 (29) 8 (23) 0.267 
Ischemiaa 9 (15) 6 (14) 8 (18) 3 (8) 9 (17) 2 (5) 3 (6) 3 (9) 0.099 
Atrial Fib/ 
flutter/PSVT 
6 (10) 10 (23) 7 (16) 4 (10) 15 (28) 13 (33) 14 (29) 8 (23) 0.427 
Bundle branch 
block 
6 (10) 4 (10) 6 (14) 4 (10) 7 (13) 4 (10) 7 (15) 7 (20) 0.359 
ST elevation 6 (10) 4 (10) 3 (7) 2 (5) 4 (7) 3 (8) 3 (6) 1 (3) 0.869 
ST depression 5 (9) 4 (10) 6 (14) 1 (3) 8 (15) 2 (5) 2 (4) 3 (9) 0.317 
T inversion 10 (16) 10 (23) 8 (18) 6 (15) 12 (22) 8 (20) 11 (23) 8 (23) 0.530 
Q wave 11 (18) 3 (7) 6 (14) 7 (18) 12 (22) 8 (20) 10 (21) 9 (26) 0.039 
Ventricular rhythm 0 (0) 0 (0) 0 (0) 0 (0) 1 (2) 0 (0) 1 (2) 0 (0) -b 
Arrhythmiac 6 (10) 10 (23) 7 (16) 4 (10) 16 (30) 13 (33) 15 (31) 8 (23) 0.339 
 
Legend for Table 5. In this table we present ECG findings at each time point for patients 
randomized to vasopressin and norepinephrine.  
 
Values are N (%). 
P-value is based on logistic mixed effects model and is for the null hypothesis of no difference in 
ECG interpretation between the treatment groups at 6 hours, day 2 and day 4, adjusted for 
baseline interpretation. 
ECG interpretation results are based only on Reader 2’s data, blinded to randomization group 
and troponin level. 
a. The reader was asked for an overall assessment of whether the ECG was normal or 
abnormal, and whether, in his opinion, the ECG changes represented ischemia.  
b. Event rate is too low for p-value calculation. 
c. Arrhythmia includes atrial fibrillation, atrial flutter, paroxysmal supraventricular 
tachyarrhythmia, and ventricular rhythm. 
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Table 6. Comparison of patients with ischemia versus no ischemia on ECG. 
 
Variable Ischemia  (N =56) 
No Ischemiaa 
(N=60) P value 
Age, years 64.1 (48.0, 77.1) 63.0 (53.5, 73.3) 0.808 
Male, N (%) 40 (71) 41 (68) 0.840 
Surgical patient, N (%) 21 (38) 25 (42) 0.706 
APACHE II 29.9 (7.5) 27.4 (8.0) 0.150 
Preexisting conditions, N (%)    
   Ischemic heart disease 10 (18) 4 (7) 0.088 
   Diabetes 13 (23) 
( 
10 (17) 0.486 
Baseline lactate 2.0 (1.6, 4.5) 2.6 (1.5, 3.9) 0.441 
More severe shockb, N (%) 28 (50) 33 (55) 0.710 
Vasopressin, N (%) 31 (55) 32 (53) 0.854 
Days alive free of mechanical 
ventilation (first 28 days) 0.0 (0.0, 13.0) 2.0 (0.0, 17.0) 0.165 
ICU stayc, days  13.0 (6.0, 31.0) 11.5 (6.0, 20.0) 0.518 
Hospital stayc, days  27.0 (11.0, 77.0) 35.5 (16.0, 77.5) 0.703 
28 day mortalityd, N (%) 
95% CI 
26 (47)  
34%-60% 
 
22 (37) 
24%-49% 
 
0.263 
90 day mortalityd, N (%) 
95% CI 
33 (60) 
47%-73% 
 
27 (45) 
32%-58% 
 
0.136 
 
Legend for Table 6. In this table we present baseline and outcome data for patients with 
ischemia and those with no ischemia on ECG. 
 
Continuous variables are presented as median and first and third quartiles. Categorical 
variables are presented as N and %. P-value is based on Fisher’s exact test or Wilcoxon rank-
sum test. Five patients had no data for ECG diagnosis of ischemia. 
a. Defined as no ischemia on any ECG for both readers. 
b. Defined as treatment with ≥15 µg/min of norepinephrine or the equivalent at randomization. 
c. ICU and Hospital stay from time of admission to ICU. 
d. Mortality outcome of one patient was unknown and excluded from the calculation.  
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